Bodal Chemicals Ltd

- Currently, Bodal Chemicals is not targeting any major capex for the next couple of years, focusing instead on consolidating the current setup and improving utilization. - Small debottlenecking or minor brownfield expansions may occur, but nothing major requiring significant fundraising. - The company is actively aiming to reduce existing term debt by INR150-175 crores by the end of the current year through scheduled repayments and asset sales. - Targeted debt-to-EBITDA ratio is near 2.5; only after achieving this leverage profile will the company consider next growth plans. - There is no explicit mention of new equity fundraising in the transcript. - The focus is on improving profitability and reducing debt before planning any new fundraising for expansion.

- No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup. - Small debottlenecking or Brownfield expansions may happen but will be very limited in scale. - Strategic land sale of about 8 acres at Rajpura to a large chlorine consumer to develop pipeline chlorine buyers, not a real estate deal but a business collaboration. - The company has about 62 acres of surplus land for future expansions, ensuring capacity for growth over the next 10-15 years. - Future growth capex will be considered after achieving a targeted debt-to-EBITDA ratio near 2.5, indicating focus on debt reduction before new investments. - Emphasis on increasing capacity utilization and improving leverage profile before undertaking major capital investments.

- Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. - Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment. - Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months. - Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26. - TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4. - Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking. - Target to raise caustic soda capacity utilization to 90%-95% in coming quarters. - Export contributes ~22% of revenue; U.S. export negligible (~1%).

- Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%. - EBITDA margin guidance is around 11% to 12%, corresponding to an operating income of about INR35 crores per quarter. - Net profit expected approx. INR70 to 80 crores for next year, implying 7% to 8% return on investment (ROI). - Two key businesses — benzene derivatives and TCCA — are expected to scale up in 3-6 months, contributing positively to margins and profitability. - Benzene business revenue expected to reach INR100 crores in FY26, potentially INR300 crores at full capacity next year. - Capacity utilization targets for chlor-alkali near 90-95% within a few quarters. - Improved pricing in TCCA anticipated by Q3/Q4 post import duty impact, helping margins further. - Debt reduction plan ongoing, targeting reduction of INR150-175 crores term debt by year-end, aiding financial health.

The transcript does not explicitly mention the current or expected order book or pending orders for Bodal Chemicals Limited. However, some relevant insights include: - TCCA production was paused due to inventory build-up but is expected to resume with clarity in future demand, likely by Q3 or Q4 of FY26. - Benzene derivatives business is ramping up, with utilization expected to reach 70-80% by Q4 FY26, indicating growing orders. - Dye Intermediates and Dyestuff divisions are maintaining volume and revenue levels with some challenges in raw material prices. - The company expects growth in turnover to INR1,900-2,100 crores in FY26, supported by existing business and new projects. - No specific figures on order book or pending orders were disclosed during the call.